The Voice of the Cruise Industry
Latest News
MENU menu

Vaccine linked to 2021 cruise return, says Mundy Cruising survey

Edwina Lonsdale, cruise, mundy cruising, coronavirus,

A new survey by Mundy Cruising has found that 81 per cent of respondents are planning to return to the seas in 2021, though the majority will wait until they have been vaccinated first.

The findings – taken from Mundy’s new Cruise Expert Panel, launched in October – follow recent announcements regarding Covid-19 vaccines.

A total of 47 per cent of the survey respondents said that they would only cruise once they had been vaccinated and the majority of the population had been vaccinated.

A a further 39 per cent said they would cruise once they had been vaccinated, even if the majority of the population had not.

Futhermore, 9 per cent said that a vaccine made no difference to their plans, indicating they would get on a “cruise ship tomorrow if they could”, while 3 per cent said they would cruise without being vaccinated, provided that the majority of the population had already had the jab.

As for when clients expect to be back on board, 30 per cent of respondents expect to cruise again in the second quarter of 2021, while 22 per cent stated the third quarter and 18 per cent between October and December 2021.

Mundy Cruising managing director Edwina Lonsdale said: “Our most recent survey has given us a lot of food for thought, but the overriding sentiment is one of cautious optimism regarding the resumption of cruising in 2021.

“Mundy clients are a well-travelled, well-informed and pragmatic bunch, so it’s no surprise to us that their responses are grounded in a realistic appraisal of where things stand.

“We know that a vaccine will take time to roll out, which is why the cruise lines are pressing ahead with their detailed and exhaustive plans to ensure that cruising post-Covid is safer than ever.

“Nevertheless, the recent flurry of good news has clearly given our clients a much-needed boost, with bookings significantly up since the vaccine announcements from Pfizer-BioNTech, Moderna and now Oxford-AstraZeneca.”

Sign In

Lost your password?